Articles related to GENITOURINARY CANCER

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

Delve into key insights from ASCO 2023, which emphasized patient-centered care in genitourinary oncology, including the efficacy of virtual prostate cancer clinics and the critical need for initiating serious-illness conversations.

Second-generation androgen receptor pathway inhibitors (ARPIs) have proven to be essential in managing nonmetastatic castration-resistant prostate cancer (nmCRPC). These treatments provide hope in delaying metastasis and improving overall survival, significantly altering the disease’s prognosis.

The decision was based on the findings of the open-label, multi-cohort, multicenter, phase 1b/2 clinical trial EV-103/KEYNOTE-869. Patients who participated in the study and were included in the current analysis had locally advanced or metastatic disease, were ineligible for cisplatin-containing chemotherapy, and had not previously received systemic therapy. The primary efficacy outcome measures for the study were the objective response rate (ORR) and duration of response (DoR), which were determined by an independent central review using RECIST v1.1. The ORR for the 121 patients treated with the combination was 68%, with 12% having a complete response. The median DoR for dose escalation was 22 months for two cohorts but not for a third.